Yifan Pharmaceutical (SHE:002019) obtained Chinese regulatory approval to begin clinical trials for teriparatide injection.
The drug, a biosimilar to Eli Lilly's Forteo, is indicated for treating osteoporosis in postmenopausal women at high fracture risk, according to a Thursday filing with the Shenzhen bourse.
Shares of the pharmaceutical company closed 3% lower Thursday.
Yunnan Tourism Co (SHE:002059) received a final arbitration award from the China International Economic and Trade Arbitration Commission (CIETAC) in a dispute with Yongzhou Xiangyuan over unpaid project fees.CIETAC ordered Yongzhou Xiangyuan to pay 32.7 million yuan in upfront fees, plus 11.9 million yuan in equipment progress payments, along with certain costs and legal fees, according to a Thursday filing with the Shenzhen bourse.However, the award denied the majority of the original 151.4 million yuan claim, including the full upfront fee of 100.0 million yuan.Shares of the tourism company closed 1% lower Thursday.
Transport International (HKG:0062) Chairman Norman Leung Nai Pang retired Thursday.As such, the bus operator re-designated Deputy Chairman Ma Siu Cheung as its new chair, according to a same-day Hong Kong bourse filing.
Guangdong Zhongsheng Pharmaceutical (SHE:002317) said China's drug regulator accepted the new drug marketing application for anladwevir granule.The drug is used to treat uncomplicated influenza A in children, according to a Thursday filing with the Shenzhen bourse.